{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,8]],"date-time":"2026-11-08T03:15:54Z","timestamp":1794107754206,"version":"4.8.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T00:00:00Z","timestamp":1750464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer J."],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Extranodal (EN) diffuse large B-cell lymphoma (DLBCL) has been historically associated with inferior survival outcomes compared to nodal DLBCL. However, outcomes of patients with EN DLBCL following chimeric antigen receptor T-cell (CAR-T) therapy are not well established. In this multi-center retrospective cohort study, we evaluated the outcomes of patients with EN DLBCL who underwent CAR-T in the relapsed\/refractory (R\/R) setting. The primary objective was overall survival (OS), while secondary objectives included progression-free survival (PFS), response rates, and toxicity rates. A total of 218 patients were included in the analysis. The most common sites of EN involvement were skin\/soft tissue (25%), bone (22%), and lung (17%). Overall response rate (ORR) and complete response rate (CRR) at first post-treatment evaluation were 62% (<jats:italic>n<\/jats:italic>\u2009=\u2009127) and 40% (<jats:italic>n<\/jats:italic>\u2009=\u200982), respectively. Median follow-up was 3.5 years. Median PFS and OS were 4.0 months (95% CI\u2009=\u20093.1\u20137.2) and 25.7 months (95% CI\u2009=\u200916.1\u201351.6), respectively. Cytokine release syndrome (CRS) of any grade occurred in 73% (<jats:italic>n<\/jats:italic>\u2009=\u2009159) of patients, and 6% (<jats:italic>n<\/jats:italic>\u2009=\u200912) had grade \u2265 3 CRS. Immune effector cell-associated neurotoxicity syndrome (ICANS) of any grade occurred in 37% (<jats:italic>n<\/jats:italic>\u2009=\u200981) of patients, and 19% (<jats:italic>n<\/jats:italic>\u2009=\u200941) developed grade\u2009\u2265\u20093 ICANS. In the multivariable analysis, factors that were independently prognostic of inferior OS were 3 or more lines of therapy prior to CAR-T, bulky disease at the time of CAR-T, hepatobiliary, and pancreas involvement, while refractory disease to the most recent therapy prior to CAR-T was associated with inferior PFS. Future studies should further evaluate outcomes of CAR-T in patients with specific EN sites of involvement that appear to be associated with inferior survival such as the liver and pancreas.<\/jats:p>","DOI":"10.1038\/s41408-025-01318-5","type":"journal-article","created":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T22:05:28Z","timestamp":1750543528000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Impact of extranodal involvement at CAR T-cell therapy on outcomes in patients with relapsed or refractory large B-cell lymphoma\u2014Results from a multicenter cohort study"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8495-8579","authenticated-orcid":false,"given":"Frederique","family":"St-Pierre","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3804-5370","authenticated-orcid":false,"given":"Subodh","family":"Bhatta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter G.","family":"Doukas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-2920-4875","authenticated-orcid":false,"given":"Madeline","family":"Jenkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlin","family":"Annunzio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra E.","family":"Rojek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyssa","family":"Gibson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8745-0906","authenticated-orcid":false,"given":"Yun Kyoung","family":"Tiger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brittany","family":"McCall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khaled","family":"Alhamad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2690-3377","authenticated-orcid":false,"given":"Juan P.","family":"Alderuccio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olutobi","family":"Adewale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keem","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2479-1797","authenticated-orcid":false,"given":"Asaad","family":"Trabolsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9346-9013","authenticated-orcid":false,"given":"Izidore S.","family":"Lossos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lindsey","family":"Fitzgerald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0102-6491","authenticated-orcid":false,"given":"Thomas A.","family":"Ollila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Matasar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Kline","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0984-4376","authenticated-orcid":false,"given":"Reem","family":"Karmali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8216-3457","authenticated-orcid":false,"given":"Narendranath","family":"Epperla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,21]]},"reference":[{"key":"1318_CR1","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1093\/annonc\/mdg004","volume":"14","author":"ADG Krol","year":"2003","unstructured":"Krol ADG, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM. Primary extranodal non-Hodgkin\u2019s lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol. 2003;14:131\u20139.","journal-title":"Ann Oncol"},{"key":"1318_CR2","doi-asserted-by":"crossref","unstructured":"Suresh Babu MC, Sreevalli A. Extranodal diffuse large B-cell lymphoma: Real-world experience from an Indian tertiary cancer center. Cancer Res Stat Treat. 2022;5:119\u2013121.","DOI":"10.4103\/crst.crst_93_22"},{"key":"1318_CR3","doi-asserted-by":"publisher","first-page":"67","DOI":"10.4103\/crst.crst_204_21","volume":"5","author":"SC Nair","year":"2022","unstructured":"Nair SC, Gogia A, Arora S, Kumar L, Sharma A, Biswas A, et al. Clinicopathologic features and outcomes of diffuse large B-cell lymphoma with extranodal involvement: a retrospective analysis. Cancer Res Stat Treat. 2022;5:67\u201374.","journal-title":"Cancer Res Stat Treat"},{"key":"1318_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s11864-018-0555-8","volume":"19","author":"TA Ollila","year":"2018","unstructured":"Ollila TA, Olszewski AJ. Extranodal diffuse large B cell lymphoma: molecular features, prognosis, and risk of central nervous system recurrence. Curr Treat Options Oncol. 2018;19:38.","journal-title":"Curr Treat Options Oncol"},{"key":"1318_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1046\/j.1365-2141.2003.04749.x","volume":"124","author":"MB M\u00f8ller","year":"2004","unstructured":"M\u00f8ller MB, Pedersen NT, Christensen BE. Diffuse large B-cell lymphoma: clinical implications of extranodal versus nodal presentation-a population-based study of 1575 cases. Br J Haematol. 2004;124:151\u20139.","journal-title":"Br J Haematol"},{"key":"1318_CR6","doi-asserted-by":"publisher","first-page":"v91","DOI":"10.1093\/annonc\/mdw175","volume":"27","author":"U Vitolo","year":"2016","unstructured":"Vitolo U, Seymour JF, Martelli M, Illerhaus G, Illidge T, Zucca E, et al. Extranodal diffuse large B-cell lymphoma (DLBCL) and primary mediastinal B-cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016;27:v91\u2013v102.","journal-title":"Ann Oncol"},{"key":"1318_CR7","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1002\/ajh.23638","volume":"89","author":"JJ Castillo","year":"2014","unstructured":"Castillo JJ, Winer ES, Olszewski AJ. Sites of extranodal involvement are prognostic in patients with diffuse large B-cell lymphoma in the rituximab era: an analysis of the Surveillance, Epidemiology and End Results database. Am J Hematol. 2014;89:310\u20134.","journal-title":"Am J Hematol"},{"key":"1318_CR8","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1002\/ajh.24169","volume":"90","author":"TC El-Galaly","year":"2015","unstructured":"El-Galaly TC, Villa D, Alzahrani M, Hansen JW, Sehn LH, Wilson D, et al. Outcome prediction by extranodal involvement, IPI, R-IPI, and NCCN-IPI in the PET\/CT and rituximab era: A Danish-Canadian study of 443 patients with diffuse-large B-cell lymphoma. Am J Hematol. 2015;90:1041\u20136.","journal-title":"Am J Hematol"},{"key":"1318_CR9","first-page":"548","volume":"29","author":"N Epperla","year":"2023","unstructured":"Epperla N, Kumar A, Abutalib SA, Awan FT, Chen Y-B, Gopal AK, et al. ASTCT Clinical Practice Recommendations for Transplantation and Cellular Therapies in Diffuse Large B Cell Lymphoma. Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther. 2023;29:548\u201355.","journal-title":"Transplant Cell Ther, Off Publ Am Soc Transplant Cell Ther"},{"key":"1318_CR10","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1056\/NEJMoa2116133","volume":"386","author":"FL Locke","year":"2022","unstructured":"Locke FL, Miklos DB, Jacobson CA, Perales M-A, Kersten M-J, Oluwole OO, et al. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma. N. Engl J Med. 2022;386:640\u201354.","journal-title":"N. Engl J Med"},{"key":"1318_CR11","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1182\/blood.2022018730","volume":"141","author":"JS Abramson","year":"2023","unstructured":"Abramson JS, Solomon SR, Arnason J, Johnston PB, Glass B, Bachanova V, et al. Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood. 2023;141:1675\u201384.","journal-title":"Blood"},{"key":"1318_CR12","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1056\/NEJMoa1804980","volume":"380","author":"SJ Schuster","year":"2019","unstructured":"Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, et al. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N. Engl J Med. 2019;380:45\u201356.","journal-title":"N. Engl J Med"},{"key":"1318_CR13","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","volume":"396","author":"JS Abramson","year":"2020","unstructured":"Abramson JS, Palomba ML, Gordon LI, Lunning MA, Wang M, Arnason J, et al. Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet. 2020;396:839\u201352.","journal-title":"Lancet"},{"key":"1318_CR14","unstructured":"Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. New England J Med. 377:2531\u201344."},{"key":"1318_CR15","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cca.2022.05.018","volume":"532","author":"Z Song","year":"2022","unstructured":"Song Z, Xu L, Tang G, Gao L, Wang L, Ni X, et al. Prognostic differences of refractory\/relapsed nodal and extranodal diffuse large B-cell lymphoma in the chimeric antigen receptor T cell therapy era. Clin Chim Acta. 2022;532:72\u20138.","journal-title":"Clin Chim Acta"},{"key":"1318_CR16","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/ejh.13968","volume":"111","author":"KO Beyar","year":"2023","unstructured":"Beyar KO, Perry C, Grisariu-Greenzaid S, Yehudai-Ofir D, Luttwak E, Avni B, et al. Response rates of extra-nodal diffuse large B cell lymphoma to anti-CD19-CAR T cells: A real word retrospective multicenter study. Eur J Haematol. 2023;111:63\u201371.","journal-title":"Eur J Haematol"},{"key":"1318_CR17","doi-asserted-by":"publisher","first-page":"581.e1","DOI":"10.1016\/j.jtct.2022.05.026","volume":"28","author":"CA Jacobson","year":"2022","unstructured":"Jacobson CA, Locke FL, Ma L, Asubonteng J, Hu ZH, Siddiqi T, et al. Real-world evidence of axicabtagene ciloleucel for the treatment of large B cell lymphoma in the United States. Transpl Cell Ther. 2022;28:581.e1\u2013e8.","journal-title":"Transpl Cell Ther"},{"key":"1318_CR18","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1182\/blood-2023-180242","volume":"142","author":"JL Crombie","year":"2023","unstructured":"Crombie JL, Nastoupil LJ, Andreadis C, Isufi I, Hunter B, Winter A, et al. Multicenter, Real-World Study in Patients with R\/R Large B-Cell Lymphoma (LBCL) Who Received Lisocabtagene Maraleucel (liso-cel) in the United States (US). Blood. 2023;142:104.","journal-title":"Blood"},{"key":"1318_CR19","doi-asserted-by":"publisher","first-page":"77.e1","DOI":"10.1016\/j.jtct.2023.10.017","volume":"30","author":"CA Jacobson","year":"2024","unstructured":"Jacobson CA, Munoz J, Sun F, Kanters S, Limbrick-Oldfield EH, Spooner C, et al. Real-world outcomes with chimeric antigen receptor T cell therapies in large B cell lymphoma: a systematic review and meta-analysis. Transpl Cell Ther. 2024;30:77.e1\u2013e15.","journal-title":"Transpl Cell Ther"},{"key":"1318_CR20","doi-asserted-by":"publisher","first-page":"3214","DOI":"10.1002\/cam4.3881","volume":"10","author":"G Iacoboni","year":"2021","unstructured":"Iacoboni G, Villacampa G, Martinez-Cibrian N, Bail\u00e9n R, Lopez Corral L, Sanchez JM, et al. Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma. Cancer Med. 2021;10:3214\u201323.","journal-title":"Cancer Med"},{"key":"1318_CR21","doi-asserted-by":"publisher","first-page":"e817","DOI":"10.1097\/HS9.0000000000000817","volume":"7","author":"CA Voltin","year":"2023","unstructured":"Voltin CA, G\u00f6del P, Beckmann L, Heger JM, Kobe C, Kutsch N, et al. Outcome prediction in patients with large B-cell lymphoma undergoing chimeric antigen receptor T-cell therapy. Hemasphere. 2023;7:e817.","journal-title":"Hemasphere"},{"key":"1318_CR22","doi-asserted-by":"crossref","unstructured":"Iacoboni G, Rejeski K, Navarro V, van Meerten T, Rampotas A, Mart\u00edn-L\u00f3pez A, et al. Site-specific analysis of extranodal involvement in large B-cell lymphoma reveals distinct efficacy with chimeric antigen receptor T-cell therapy. Leukemia. 2025.","DOI":"10.1038\/s41375-025-02582-x"},{"key":"1318_CR23","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ejca.2018.01.073","volume":"93","author":"TC El-Galaly","year":"2018","unstructured":"El-Galaly TC, Cheah CY, Bendtsen MD, Nowakowski GS, Kansara R, Savage KJ, et al. Treatment strategies, outcomes and prognostic factors in 291 patients with secondary CNS involvement by diffuse large B-cell lymphoma. Eur J Cancer. 2018;93:57\u201368.","journal-title":"Eur J Cancer"},{"key":"1318_CR24","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s13045-023-01508-3","volume":"16","author":"N Epperla","year":"2023","unstructured":"Epperla N, Feng L, Shah NN, Fitzgerald L, Shah H, Stephens DM, et al. Outcomes of patients with secondary central nervous system lymphoma following CAR T-cell therapy: a multicenter cohort study. J Hematol Oncol. 2023;16:111.","journal-title":"J Hematol Oncol"},{"key":"1318_CR25","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/bjh.19569","volume":"205","author":"N Epperla","year":"2024","unstructured":"Epperla N, Hashmi H, Ahn KW, Allbee-Johnson M, Chen AI, Wirk B, et al. Outcomes of patients with secondary central nervous system lymphoma treated with chimeric antigen receptor T-cell therapy: A CIBMTR analysis. Br J Haematol. 2024;205:1202\u20137.","journal-title":"Br J Haematol"}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01318-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01318-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01318-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T22:05:30Z","timestamp":1750543530000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-025-01318-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,21]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1318"],"URL":"https:\/\/doi.org\/10.1038\/s41408-025-01318-5","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,21]]},"assertion":[{"value":"23 December 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 June 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"NE: Research Funding (institution) from Beigene, ADC Therapeutics, Lilly, Incyte, and Ipsen. Advisory board for Genentech, CRISPR Therapeutics and Ipsen. RK: Advisory Board: BMS, Genentech\/Roche, Abbvie, GenMab; Speakers Bureau: BeiGene, AstraZeneca, BMS. JPA: Research support: ADC Therapeutics, Genmab, AbbVie, and BeiGene. Consultancy: ADC Therapeutics, Genentech, AbbVie, Lilly, Novartis, and Regeneron. TAO: Ad board for ADC therapeutics, Honoraria and research support for ONO pharmaceuticals.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Permission granted by Wiley to reproduce Fig.  from: .","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Third party material"}}],"article-number":"110"}}